# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers

> **NCT02757144** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 120 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWP14012
- **DRUG:** Placebo
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT02757144
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757144, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02757144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*